These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
349 related articles for article (PubMed ID: 22535375)
1. Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer. Ivanova T; Zouridis H; Wu Y; Cheng LL; Tan IB; Gopalakrishnan V; Ooi CH; Lee J; Qin L; Wu J; Lee M; Rha SY; Huang D; Liem N; Yeoh KG; Yong WP; Teh BT; Tan P Gut; 2013 Jan; 62(1):22-33. PubMed ID: 22535375 [TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer. Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380 [TBL] [Abstract][Full Text] [Related]
3. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro. Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892 [TBL] [Abstract][Full Text] [Related]
4. Epigenetic inactivation of BCL6B, a novel functional tumour suppressor for gastric cancer, is associated with poor survival. Xu L; Li X; Chu ES; Zhao G; Go MY; Tao Q; Jin H; Zeng Z; Sung JJ; Yu J Gut; 2012 Jul; 61(7):977-85. PubMed ID: 21917650 [TBL] [Abstract][Full Text] [Related]
5. Gene expression profiling for analysis acquired oxaliplatin resistant factors in human gastric carcinoma TSGH-S3 cells: the role of IL-6 signaling and Nrf2/AKR1C axis identification. Chen CC; Chu CB; Liu KJ; Huang CY; Chang JY; Pan WY; Chen HH; Cheng YH; Lee KD; Chen MF; Kuo CC; Chen LT Biochem Pharmacol; 2013 Oct; 86(7):872-87. PubMed ID: 23933386 [TBL] [Abstract][Full Text] [Related]
6. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer. Ibanez de Caceres I; Cortes-Sempere M; Moratilla C; Machado-Pinilla R; Rodriguez-Fanjul V; Manguán-García C; Cejas P; López-Ríos F; Paz-Ares L; de CastroCarpeño J; Nistal M; Belda-Iniesta C; Perona R Oncogene; 2010 Mar; 29(11):1681-90. PubMed ID: 20023704 [TBL] [Abstract][Full Text] [Related]
7. DNA methyltransferase 1 as a predictive biomarker and potential therapeutic target for chemotherapy in gastric cancer. Mutze K; Langer R; Schumacher F; Becker K; Ott K; Novotny A; Hapfelmeier A; Höfler H; Keller G Eur J Cancer; 2011 Aug; 47(12):1817-25. PubMed ID: 21458988 [TBL] [Abstract][Full Text] [Related]
8. GSTP1 determines cis-platinum cytotoxicity in gastric adenocarcinoma MGC803 cells: regulation by promoter methylation and extracellular regulated kinase signaling. Zhang Y; Qu X; Jing W; Hu X; Yang X; Hou K; Teng Y; Zhang J; Liu Y Anticancer Drugs; 2009 Mar; 20(3):208-14. PubMed ID: 19396019 [TBL] [Abstract][Full Text] [Related]
9. Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. Lei Z; Tan IB; Das K; Deng N; Zouridis H; Pattison S; Chua C; Feng Z; Guan YK; Ooi CH; Ivanova T; Zhang S; Lee M; Wu J; Ngo A; Manesh S; Tan E; Teh BT; So JB; Goh LK; Boussioutas A; Lim TK; Flotow H; Tan P; Rozen SG Gastroenterology; 2013 Sep; 145(3):554-65. PubMed ID: 23684942 [TBL] [Abstract][Full Text] [Related]
10. Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer. Scurr LL; Guminski AD; Chiew YE; Balleine RL; Sharma R; Lei Y; Pryor K; Wain GV; Brand A; Byth K; Kennedy C; Rizos H; Harnett PR; deFazio A Clin Cancer Res; 2008 Nov; 14(21):6924-32. PubMed ID: 18980987 [TBL] [Abstract][Full Text] [Related]
11. Role of neurofilament light polypeptide in head and neck cancer chemoresistance. Chen B; Chen J; House MG; Cullen KJ; Nephew KP; Guo Z Mol Cancer Res; 2012 Mar; 10(3):305-15. PubMed ID: 22246235 [TBL] [Abstract][Full Text] [Related]
12. Enhanced expression of nuclear factor I/B in oxaliplatin-resistant human cancer cell lines. Kashiwagi E; Izumi H; Yasuniwa Y; Baba R; Doi Y; Kidani A; Arao T; Nishio K; Naito S; Kohno K Cancer Sci; 2011 Feb; 102(2):382-6. PubMed ID: 21087353 [TBL] [Abstract][Full Text] [Related]
13. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin. Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583 [TBL] [Abstract][Full Text] [Related]
14. Overexpression of IFITM1 has clinicopathologic effects on gastric cancer and is regulated by an epigenetic mechanism. Lee J; Goh SH; Song N; Hwang JA; Nam S; Choi IJ; Shin A; Kim IH; Ju MH; Jeong JS; Lee YS Am J Pathol; 2012 Jul; 181(1):43-52. PubMed ID: 22609115 [TBL] [Abstract][Full Text] [Related]
15. Identification and functional analysis of genes which confer resistance to cisplatin in tumor cells. Wu ZZ; Lu HP; Chao CC Biochem Pharmacol; 2010 Jul; 80(2):262-76. PubMed ID: 20361941 [TBL] [Abstract][Full Text] [Related]
16. Proteomics-based identification of secreted protein dihydrodiol dehydrogenase 2 as a potential biomarker for predicting cisplatin efficacy in advanced NSCLC patients. Kuang P; Zhou C; Li X; Ren S; Li B; Wang Y; Li J; Tang L; Zhang J; Zhao Y Lung Cancer; 2012 Aug; 77(2):427-32. PubMed ID: 22534668 [TBL] [Abstract][Full Text] [Related]
17. WNT6 is a novel target gene of caveolin-1 promoting chemoresistance to epirubicin in human gastric cancer cells. Yuan G; Regel I; Lian F; Friedrich T; Hitkova I; Hofheinz RD; Ströbel P; Langer R; Keller G; Röcken C; Zimmermann W; Schmid RM; Ebert MP; Burgermeister E Oncogene; 2013 Jan; 32(3):375-87. PubMed ID: 22370641 [TBL] [Abstract][Full Text] [Related]
18. An integrative approach identified genes associated with drug response in gastric cancer. Zhou J; Yong WP; Yap CS; Vijayaraghavan A; Sinha RA; Singh BK; Xiu S; Manesh S; Ngo A; Lim A; Ang C; Xie C; Wong FY; Lin SJ; Wan WK; Tan IB; Flotow H; Tan P; Lim KH; Yen PM; Goh LK Carcinogenesis; 2015 Apr; 36(4):441-51. PubMed ID: 25742747 [TBL] [Abstract][Full Text] [Related]
19. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells. Stordal BK; Davey MW; Davey RA Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310 [TBL] [Abstract][Full Text] [Related]
20. Concentration-dependent collateral sensitivity of cisplatin-resistant gastric cancer cell sublines. Xu H; Choi SM; An CS; Min YD; Kim KC; Kim KJ; Choi CH Biochem Biophys Res Commun; 2005 Mar; 328(2):618-22. PubMed ID: 15694393 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]